Abstract de artículo recomendado por el Dr. Louis Ignarro relacionado con el tema nutricional, atrofia cerebral y Alzheimers.
El estudio establecio despues de 24 meses y 271 pacientes por encima de los 70 años con un impedimiento cognitivo moderado, que el uso de Acido fólico (0.8 mg/d) Vitamina B12 (0.5 mg/d) y vitamina B6 (20 mg/d) redujo significativamente el promedio del avance de atrofia cerebral por año (0.76%) al compararse con pacientes placebo (1.08%). El efecto se encontro relacionado con el nivel basal de homocysteina. Se concluye que la atrofia cerebral en pacientes con impedimento cognitivo puede reducirse significativamente con el uso de vitaminas del complejo B.
Recordemos que las vitaminas del complejo B estan en carnes, el hígado,
el pescado, los productos lácteos, el pollo, las habichuelas y
las lentejas, la levadura de cerveza, los huevos, los vegetales de
hojas color verde oscuro, y los cereales integrales.
No hay que
esperar a tener problemas avanzados para empezar a alimentarse bien.
Aunque no tenga nada todavía, empiece hoy mismo a mejorar su nutrición.
Si conoce a alguien con estos problemas recomiendele este artículo.
Artículo completo del Dr. Ignarro
Recordemos que las vitaminas del complejo B estan en carnes, el hígado, el pescado, los productos lácteos, el pollo, las habichuelas y las lentejas, la levadura de cerveza, los huevos, los vegetales de hojas color verde oscuro, y los cereales integrales.
No hay que esperar a tener problemas avanzados para empezar a alimentarse bien. Aunque no tenga nada todavía, empiece hoy mismo a mejorar su nutrición. Si conoce a alguien con estos problemas recomiendele este artículo.
B Vitamins that Lower Homocysteine Slow Brain Atrophy in Elderly with Mild Cognitive Impairment
Summary: In a single-center, randomized, double-blind,
placebo-controlled trial involving 271 subjects over 70 years of age
with mild cognitive impairment, supplementation with folic acid (0.8
mg/d), vitamin B(12) (0.5 mg/d), and vitamin B(6) (20 mg/d), for a
period of 24 months, was found to be associated with significantly lower
mean rate of brain atrophy per year (0.76%), as compared to subjects
receiving placebo (1.08%). The authors point out that the treatment
response was related to baseline homocysteine levels; i.e., subjects
with baseline homocysteine levels > 13 micromol/L, were found to have
a 53% lower rate of brain atrophy in the active treatment group. The
authors conclude, "The accelerated rate of brain atrophy in elderly with
mild cognitive impairment can be slowed by treatment with
homocysteine-lowering B vitamins." Given that fact that, "Sixteen
percent of those over 70 y old have mild cognitive impairment and half
of these develop Alzheimer's disease," these results are significant.
The authors add, "Since accelerated brain atrophy is a characteristic of
subjects with mild cognitive impairment who convert to Alzheimer's
disease, trials are needed to see if the same treatment will delay the
development of Alzheimer's disease."
Referencia/Reference:
"Homocysteine-lowering by B vitamins slows the rate of accelerated brain
atrophy in mild cognitive impairment: a randomized controlled trial,"
Smith AD, Smith SM, et al, PLoS One, 2010; 5(9): e12244.
Summary: In a single-center, randomized, double-blind, placebo-controlled trial involving 271 subjects over 70 years of age with mild cognitive impairment, supplementation with folic acid (0.8 mg/d), vitamin B(12) (0.5 mg/d), and vitamin B(6) (20 mg/d), for a period of 24 months, was found to be associated with significantly lower mean rate of brain atrophy per year (0.76%), as compared to subjects receiving placebo (1.08%). The authors point out that the treatment response was related to baseline homocysteine levels; i.e., subjects with baseline homocysteine levels > 13 micromol/L, were found to have a 53% lower rate of brain atrophy in the active treatment group. The authors conclude, "The accelerated rate of brain atrophy in elderly with mild cognitive impairment can be slowed by treatment with homocysteine-lowering B vitamins." Given that fact that, "Sixteen percent of those over 70 y old have mild cognitive impairment and half of these develop Alzheimer's disease," these results are significant. The authors add, "Since accelerated brain atrophy is a characteristic of subjects with mild cognitive impairment who convert to Alzheimer's disease, trials are needed to see if the same treatment will delay the development of Alzheimer's disease."
Referencia/Reference: "Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial," Smith AD, Smith SM, et al, PLoS One, 2010; 5(9): e12244.
